about
Attenuation of counterregulatory responses to recurrent hypoglycemia by active thalamic inhibition: a mechanism for hypoglycemia-associated autonomic failure.Striatal dopamine D1-like receptor binding is unchanged in primary focal dystonia.Autoregulation after ischaemic stroke.Cerebellum as the normal reference for the detection of increased cerebral oxygen extraction.Autoregulation of cerebral blood flow to changes in arterial pressure in mild Alzheimer's disease.Mapping Go-No-Go performance within the subthalamic nucleus region.A possible substrate for dopamine-related changes in mood and behavior: prefrontal and limbic effects of a D3-preferring dopamine agonistDynamic susceptibility contrast MRI with localized arterial input functions.Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primatesDecreased striatal dopamine receptor binding in primary focal dystonia: a D2 or D3 defect?Surgical results of the Carotid Occlusion Surgery Study.Platelet mitochondrial complex I and I+III activities do not correlate with cerebral mitochondrial oxidative metabolism.Metabolic control of resting hemispheric cerebral blood flow is oxidative, not glycolyticSelective defect of in vivo glycolysis in early Huntington's disease striatumEffect of osmotic agents on regional cerebral blood flow in traumatic brain injury.Mood response to deep brain stimulation of the subthalamic nucleus in Parkinson's diseaseCharacterization of extrastriatal D2 in vivo specific binding of [¹⁸F](N-methyl)benperidol using PET.Normal platelet mitochondrial complex I activity in Huntington's disease.Thalamic activation during slightly subphysiological glycemia in humans.Validation of the reference tissue model for estimation of dopaminergic D2-like receptor binding with [18F](N-methyl)benperidol in humansExtracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial.Validation of nigrostriatal positron emission tomography measures: critical limits.Reduced uptake of FDOPA PET in end-stage liver disease with elevated manganese levelsPatterns of infarction in hemodynamic failure.Perfusion CT compared to H(2) (15)O/O (15)O PET in patients with chronic cervical carotid artery occlusion.Cerebral mitochondrial metabolism in early Parkinson's diseasePoor correlation between perihematomal MRI hyperintensity and brain swelling after intracerebral hemorrhage.[18F]FDOPA PET as an endophenotype for Parkinson's Disease linkage studiesComparison of induced hypertension, fluid bolus, and blood transfusion to augment cerebral oxygen delivery after subarachnoid hemorrhagePrincipal component analysis of PiB distribution in Parkinson and Alzheimer diseases.No effect of low-dose statins treatment on cerebral blood flow in humans with atherosclerotic cerebrovascular disease.Red blood cell transfusion increases cerebral oxygen delivery in anemic patients with subarachnoid hemorrhage.Cerebral hemodynamics as a predictor of stroke in adult patients with moyamoya disease: a prospective observational study.Randomized Evaluation of Carotid Occlusion and Neurocognition (RECON) trial: main results.Activation of human medial prefrontal cortex during autonomic responses to hypoglycemia.Lower stroke risk with lower blood pressure in hemodynamic cerebral ischemia.Relative Mean Transit Time Predicts Subsequent Stroke in Symptomatic Carotid Occlusion.Effect of mannitol on cerebral blood volume in patients with head injuryValidation of a fiducial-based atlas localization method for deep brain stimulation contacts in the area of the subthalamic nucleus.[18F]FDOPA PET and clinical features in parkinsonism due to manganism.
P50
Q31136480-CA0C0D29-EF31-4EDD-9518-A88EBEBC29E7Q33863502-16D824FB-68B2-4C8F-8C13-0C4CFFB04054Q33925362-1A6FD410-8865-41A7-8748-6906342DA29EQ34168510-60C018E6-1692-4A46-A45B-CF5123C708B8Q34274037-6FE2212B-9C11-4B1C-BACA-1922F86DF565Q34372958-0B19C5B3-9C93-4E60-A8A5-F0B37C5C3D69Q34431032-50F0B31F-A90D-497F-AC6B-BDB1294D3A8CQ34460150-EC3DD6A1-831A-4219-AD3B-A16B25C3C60FQ34473392-70193812-DE62-4AD6-9439-31A6AD953C30Q34512173-089C75B0-B356-48F0-9C75-5615ACD30329Q34583758-CB4D8C27-72C1-4BAB-AF97-05B40E1DF3ABQ34627459-89C6C8A1-2F53-4B10-B6C4-2FE61A25C355Q34997960-73E12CD5-3A1B-4E84-9C01-6638FF8DA85BQ35634060-6D5EDDDB-E479-4692-9C81-2E43C26E1BE8Q35848334-7935F1CC-8E9A-4AAD-A6E7-333A2B63F58AQ35968225-75F042D1-6B8E-4851-8DFB-506F64F00B2AQ36075795-85DF279E-01ED-4947-89D1-595E1D9137A8Q36274461-29197EB0-E7BD-4242-BFD1-50C36564099DQ36426687-6ECA6AD3-47A6-4A11-BC20-443F4F2DA657Q36666227-AC241061-7F73-429F-9426-08A6C5D725DEQ36697448-D130569B-3965-4A8A-95EA-321DEC63F979Q36780857-3AF30538-FDE1-48B9-956F-697F5C659F0FQ36817049-B51D3CE1-1A61-4DD4-9B13-B72390FD8BE5Q36829307-8D50C9B7-6504-43DA-B79B-95521A512BD2Q36980831-F1066A54-6B93-4E15-9E19-7DF818A27EA6Q37001813-7F77FF6D-95F0-4041-824D-660D1E4DEBFBQ37022968-9A8B98E8-8BA2-4AB2-A7DC-3B3439BEB7C8Q37105104-D3F882C9-B305-496E-83B5-976344641CD8Q37148901-7F9C0509-306D-49EF-97D1-F650F6173A00Q37178758-CB7AA164-EA32-426D-8617-22B991777066Q37188060-AB27CC75-0115-4BAD-B130-D4D716651FFEQ37342862-E0EABD16-A0B5-4B54-8569-E5BCB5A093BEQ37354926-1CD8489A-3406-4875-BD7A-46DA14C76894Q37623189-D94811B7-9E96-45A4-A283-F12506C1B076Q37647593-32444C8C-5E77-4E2C-A2DF-C53A8534E104Q37657027-8BB4A19B-96E5-4971-B9F5-0A863AFD8D3BQ39884092-B8249EF3-5365-4EA1-9665-3BADFFC19C0BQ41824021-0F04F880-3029-43A3-B0DE-0827EE04F08BQ43076207-80FCF656-E875-4B9A-B7C3-01FE4443174FQ45222225-B6396CEF-520F-4FA7-80AE-393DCDCDA4C8
P50
name
Tom O Videen
@ast
Tom O Videen
@en
Tom O Videen
@nl
type
label
Tom O Videen
@ast
Tom O Videen
@en
Tom O Videen
@nl
prefLabel
Tom O Videen
@ast
Tom O Videen
@en
Tom O Videen
@nl